Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis.

ABSTRACT:

Background

Direct oral anticoagulants (DOACs) have emerged as the first-line therapy for venous thromboembolism and stroke prophylaxis in atrial fibrillation. As DOACs are partially excreted renally, their safety in patients with chronic kidney disease (CKD) is unclear.

Objectives

To synthesize primary evidence on the safety profile of DOACs in patients with CKD.

Methods

We searched MEDLINE and Embase from inception to June 2023 for randomized and nonrandomized cohort studies comparing DOACs with vitamin K antagonists (VKAs) in CKD patients. Screening and data collection were conducted in duplicate. The primary safety outcome was major bleeding, defined by International Society on Thrombosis and Haemostasis criteria, stratified by CKD severity. Meta-analysis was done

SUBMITTER: Tham D 

PROVIDER: S-EPMC11577179 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature